EurekAlert -- A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol™, produces a pronounced reduction of malignant melanoma cell growth. Dermytol™, a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer. Mal Evans, DVM, MSc, PhD, KGK Synergize Inc’s Scientific Director, said, “Skin cancer rates have been rising, and we are likely to see that continue as the population ages. The National Cancer Institute (NCI) estimates that more than 62,000 Americans will be diagnosed with melanoma and one million Americans will be diagnosed with non-melanoma skin cancer this year. NCI expects more than 8,000 deaths from melanoma and less than 1,000 deaths from non-melanoma cancers this year.
